. Author manuscript; available in PMC: 2020 Dec 5.

Published in final edited form as: Lancet HIV. 2019 Dec 6:S2352-3018(19)30337-6. doi: 10.1016/S2352-3018(19)30337-6

Table 2:

Virologic failure (≥400 copies/µL) by randomization arm and HIV drug-resistance mutation frequency

Pretreatment drug resistance: categorization and mutant frequency	OLA-guided therapy		Standard of Care		p-value
	N tested	n (%) VF	N tested	n (%) VF	p-value
Total	400	34 (9%)	403	39 (10%)	0·56

Wild-type; <2%	361	28 (8%)	372	24 (7%)	0·49

Low frequency resistance; 2–9%	4^*	1 (25%)	5^*	2 (40%)	0·64

Resistant; ≥10%	35^{^}	5 (14%)	26^*	13 (50%)	<0·01

Abbreviations: OLA, oligonucleotide ligation assay; VF, virologic failure;

prescribed NNRTI-based ART;

^{^}

only participants prescribed 2^nd-line PI-based ART